UK-based Scancell Holdings Plc has raised £6.1 million from a private share placement and an open offer to shareholders enabling it to make plans to start a combination study of its lead cancer vaccine called SCIB1 and a checkpoint inhibitor. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
